Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 527 shares of common stock at a weighted average price of $27.5372 per share on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 1, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 527 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The shares were sold at prices ranging from $27.52 to $27.54, with a weighted average sale price of $27.5372.
• Following the transaction, Lyssikatos indirectly owns 1,077,409 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a company officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale, but is unlikely to have a significant impact.

Key Dates